丙型肝炎药物市场规模、份额及成长分析(按药物类别、给药途径、疾病类型和地区)-产业预测,2025 年至 2032 年
市场调查报告书
商品编码
1789216

丙型肝炎药物市场规模、份额及成长分析(按药物类别、给药途径、疾病类型和地区)-产业预测,2025 年至 2032 年

Hepatitis C Drugs Market Size, Share, and Growth Analysis, By Drug Class (direct acting antiviral (NS3/4A protease inhibitor, NS5A inhibitor)), By Routes of Administration (oral, injectable), By Disease Type, By Region - Industry Forecast 2025-2032

出版日期: | 出版商: SkyQuest | 英文 198 Pages | 商品交期: 3-5个工作天内

价格
简介目录

预计 2023 年全球丙型肝炎治疗市场价值将达到 125 亿美元,并从 2024 年的 130.2 亿美元增长到 2032 年的 180.5 亿美元,预测期内(2025-2032 年)的复合年增长率为 4.2%。

全球丙型肝炎治疗市场正经历着动态成长,这得益于人们认识的提高、诊断技术的进步和有效治疗方案的出现。丙型肝炎盛行率的上升推动了对抗病毒治疗的需求,尤其是在老年人等弱势群体中。政府和医疗机构为消灭病毒所做的努力进一步促进了市场扩张。公共卫生宣传活动越来越注重对高风险族群进行疾病和可用治疗方法的教育。技术创新极大地改变了市场,例如直接抗病毒药物 (DAA) 的出现,其治癒率超过 95%,缩短了治疗时间,并最大限度地减少了副作用。此外,泛基因型 DAA 和固定剂量组合药物等创新提高了治疗的便利性和依从性,从而能够为更广泛的患者群体提供有效的治疗。

目录

介绍

  • 调查目标
  • 调查范围
  • 定义

调查方法

  • 资讯收集
  • 二次资料和一次资料方法
  • 市场规模预测
  • 市场假设与约束

执行摘要

  • 全球市场展望
  • 供需趋势分析
  • 细分机会分析

市场动态与展望

  • 市场概览
  • 市场规模
  • 市场动态
    • 驱动因素和机会
    • 限制与挑战
  • 波特的分析

关键市场考察

  • 关键成功因素
  • 竞争程度
  • 关键投资机会
  • 市场生态系统
  • 市场吸引力指数(2024年)
  • PESTEL分析
  • 总体经济指标
  • 价值链分析
  • 定价分析
  • 案例研究
  • 顾客购买行为分析

丙型肝炎药物市场规模(依药物类别划分)及复合年增长率(2025-2032)

  • 市场概览
  • 直接抗病毒药物
    • NS3/4A蛋白酶抑制剂
    • NS5A抑制剂
    • NS5B聚合酵素抑制剂
  • 联合治疗
  • 干扰素
  • 其他的

丙型肝炎药物市场规模(依给药途径划分)及复合年增长率(2025-2032)

  • 市场概览
  • 口服
  • 注射
  • 其他的

丙型肝炎药物市场规模(依疾病类型划分)及复合年增长率(2025-2032)

  • 市场概览
  • 慢性C型肝炎
  • 急性C型肝炎

丙型肝炎药物市场规模(按地区)及复合年增长率(2025-2032)

  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 德国
    • 西班牙
    • 法国
    • 英国
    • 义大利
    • 其他欧洲国家地区
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 其他亚太地区
  • 拉丁美洲
    • 巴西
    • 其他拉丁美洲地区
  • 中东和非洲
    • 海湾合作委员会国家
    • 南非
    • 其他中东和非洲地区

竞争资讯

  • 前五大公司对比
  • 主要企业市场定位(2024年)
  • 主要市场参与者所采取的策略
  • 近期市场趋势
  • 公司市场占有率分析(2024年)
  • 主要企业简介
    • 公司详情
    • 产品系列分析
    • 按部门分類的公司份额分析
    • 收益同比对比(2022-2024 年)

主要企业简介

  • Pfizer(USA)
  • AbbVie(USA)
  • Gilead Sciences(USA)
  • Roche(Switzerland)
  • Johnson and Johnson(USA)
  • Novo Nordisk(Denmark)
  • Hepion Pharmaceutical(USA)
  • Vir Biotechnology(USA)
  • Teva Pharmaceutical(Israel)
  • Bristol Myers Squibb(USA)
  • Merck(USA)
  • AstraZeneca(UK)
  • GlaxoSmithKline(UK)
  • Sanofi(France)

结论和建议

简介目录
Product Code: SQMIG35I2434

Global Hepatitis C Drugs Market size was valued at USD 12.5 Billion in 2023 poised to grow from USD 13.02 in 2024 to USD 18.05 Billion by 2032, growing at a CAGR of 4.2% in the forecast period (2025-2032).

The global hepatitis C drugs market is experiencing dynamic growth, fueled by increased awareness, enhanced diagnostic advancements, and effective treatment options. The rising prevalence of hepatitis C infections is propelling demand for antiviral therapies, especially among demographics with higher infection rates, such as the elderly. Efforts from governments and healthcare organizations aimed at eradicating the virus further contribute to market expansion. Public health campaigns are increasingly focusing on educating high-risk populations about the disease and available treatments. Technological advancements have transformed the market with the emergence of direct-acting antivirals (DAAs) that achieve over 95% cure rates, reduce treatment durations, and minimize side effects. Innovations like pan-genotypic DAAs and fixed-dose combinations enhance treatment convenience and compliance, ensuring broader access to effective therapies.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Hepatitis C Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Hepatitis C Drugs Market Segments Analysis

The hepatitis C drugs market is segmented based on drug class, routes of administration, disease type and region. In terms of drug class, the market is segmented into direct acting antivirals (NS3/4A protease inhibitor, NS5A inhibitor, NS5B polymerase inhibitor), combination therapy, interferons, and others. Based on routes of administration, the market is segmented into oral, injectable, and others. Based on disease type, the market is bifurcated into chronic hepatitis C and acute hepatitis C. Based on region, the market is segmented into North America, Europe, Asia-Pacific, Central & South America and the Middle East & Africa.

Driver of the Global Hepatitis C Drugs Market

The growing prevalence of hepatitis C worldwide is significantly boosting the need for effective therapies, driven by factors such as intravenous drug use and unsafe medical procedures. As more individuals are diagnosed with this viral infection, the urgency for advanced treatment solutions intensifies. Additionally, increased awareness about the disease and its potential complications further propels the market for hepatitis C medications. Healthcare providers are focusing on improving screening and treatment options, leading to a greater demand for innovative drug formulations and therapies in the market, reflecting an overarching commitment to managing and ultimately eradicating this public health concern.

Restraints in the Global Hepatitis C Drugs Market

A major challenge facing the global hepatitis C drugs market is the high cost of direct-acting antiviral (DAA) medications, which remains a hurdle for widespread treatment in regions where healthcare budgets are constrained. In many countries, limited financial resources hinder healthcare systems from providing universal access to these essential drugs, despite some efforts to lower prices through competition and government negotiations. As a result, the economic burden associated with hepatitis C treatment continues to restrict access, leaving many patients without the necessary therapies and impeding progress toward eradicating the disease on a global scale.

Market Trends of the Global Hepatitis C Drugs Market

The global Hepatitis C drugs market is witnessing a marked transition toward affordable Direct-Acting Antivirals (DAAs) and generic formulations, driven by the expiration of patents and the implementation of voluntary licensing agreements. This trend is particularly significant in low- and middle-income countries, where access to cost-effective treatment options is crucial for controlling the virus. Enhanced affordability is pivotal, aligning with the World Health Organization's goals for Hepatitis C elimination, as it fosters increased treatment rates and expands the positive impact on public health. The increased availability of generics is reshaping the competitive landscape and facilitating broader access to lifesaving therapies.

Table of Contents

Introduction

  • Objectives of the Study
  • Scope of the Report
  • Definitions

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Methods
  • Market Size Estimation
  • Market Assumptions & Limitations

Executive Summary

  • Global Market Outlook
  • Supply & Demand Trend Analysis
  • Segmental Opportunity Analysis

Market Dynamics & Outlook

  • Market Overview
  • Market Size
  • Market Dynamics
    • Drivers & Opportunities
    • Restraints & Challenges
  • Porters Analysis
    • Competitive rivalry
    • Threat of substitute
    • Bargaining power of buyers
    • Threat of new entrants
    • Bargaining power of suppliers

Key Market Insights

  • Key Success Factors
  • Degree of Competition
  • Top Investment Pockets
  • Market Ecosystem
  • Market Attractiveness Index, 2024
  • PESTEL Analysis
  • Macro-Economic Indicators
  • Value Chain Analysis
  • Pricing Analysis
  • Case Studies
  • Customer Buying Behavior Analysis

Global Hepatitis C Drugs Market Size by Drug Class & CAGR (2025-2032)

  • Market Overview
  • Direct Acting Antiviral
    • NS3/4A Protease Inhibitor
    • NS5A Inhibitor
    • NS5B Polymerase Inhibitor
  • Combination Therapy
  • Interferons
  • Others

Global Hepatitis C Drugs Market Size by Routes of Administration & CAGR (2025-2032)

  • Market Overview
  • Oral
  • Injectable
  • Others

Global Hepatitis C Drugs Market Size by Disease Type & CAGR (2025-2032)

  • Market Overview
  • Chronic Hepatitis C
  • Acute Hepatitis C

Global Hepatitis C Drugs Market Size & CAGR (2025-2032)

  • North America (Drug Class, Routes of Administration, Disease Type)
    • US
    • Canada
  • Europe (Drug Class, Routes of Administration, Disease Type)
    • Germany
    • Spain
    • France
    • UK
    • Italy
    • Rest of Europe
  • Asia Pacific (Drug Class, Routes of Administration, Disease Type)
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America (Drug Class, Routes of Administration, Disease Type)
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (Drug Class, Routes of Administration, Disease Type)
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

Competitive Intelligence

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2024
  • Strategies Adopted by Key Market Players
  • Recent Developments in the Market
  • Company Market Share Analysis, 2024
  • Company Profiles of All Key Players
    • Company Details
    • Product Portfolio Analysis
    • Company's Segmental Share Analysis
    • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

  • Pfizer (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • AbbVie (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Gilead Sciences (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Roche (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Johnson and Johnson (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Novo Nordisk (Denmark)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Hepion Pharmaceutical (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Vir Biotechnology (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Teva Pharmaceutical (Israel)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bristol Myers Squibb (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Merck (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • AstraZeneca (UK)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • GlaxoSmithKline (UK)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Sanofi (France)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments

Conclusion & Recommendations